Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.45 |
| ▸ | F10 | P00742 | 7/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348339 | 0.88 | MAPT (0.51) | TP53F10PRSS1MAPT | |
| SCHEMBL5163876 | 0.83 | F10 (0.45) | F10PRSS1PLAUHPN | |
| SCHEMBL5164416 | 0.82 | F10 (0.48) | F10PRSS1PLAUHPN | |
| SCHEMBL5163949 | 0.82 | F10 (0.48) | F10PRSS1PLAUHPN | |
| SCHEMBL5167890 | 0.82 | F10 (0.47) | F10PRSS1PLAUHPN | |
| SCHEMBL5164832 | 0.82 | F10 (0.47) | F10PRSS1PLAUHPN | |
| SCHEMBL5349981 | 0.77 | F10 (0.50) | TP53F10PRSS1MAPT | |
| SCHEMBL5349961 | 0.77 | TP53 (0.39) | TP53F10MAPT | |
| SCHEMBL5166099 | 0.76 | F10 (0.49) | F10PRSS1PLAU | |
| SCHEMBL5165742 | 0.76 | F10 (0.52) | TP53F10PRSS1PLAUHPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199133-B2 | Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GESELLSCHAFT (DE) | 2007-04-03 | — | — | US | claimed |
| EP-1441726-B1 | DERIVATIVES OF PHENOXY-N-'4-(ISOTHIAZOLIDIN-1,1-DIOXID-2YL)PHENY]-VALERIAN- ACID AMIDE AND OTHER COMPOUNDS AS INHIBITORS OF THE COAGULATION FACTOR XA IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2006-12-20 | — | — | EP | claimed |
| US-20040254175-A1 | Derivatives of phenoxy-n-'4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2004-12-16 | — | — | US | claimed |
| US-7199133-B2 | Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20040254175-A1 | Derivatives of phenoxy-n-'4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254175-A1 | Derivatives of phenoxy-n-'4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | F2, F11, SERPINC1 | TP53 1323/4885F10 4/4885PRSS1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.